Dr. Sara Tolaney details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.
My name is Sarah Tlani. I'm a breast medical oncologist at Dana-Farber Cancer Institute and at ESO this year, we saw data from Ascent 03. This study specifically looked at the use of sactuzumab Gobatan and compared it to standard chemotherapy in patients who were getting treated in the first line metastatic triple negative setting. And there were patients who had tumors that were PDL1 negative or were patients who were ineligible to receive further checkpoint inhibition. We already had known that scetuzumab Gobatan was more effective than standard chemotherapy in the pre-treated metastatic triple negative breast cancer setting. And it is a drug that is FDA approved to be utilized in the second line or later, but this trial is really looking to see if it could be utilized in the first line setting. And what we saw was that Satuzumab did do better than standard chemotherapy with an improvement in progression-free survival from 6.9 to 9.7 months, so that was consistent with the hazard ratio of 0.62. Um, so I think really nice to see in this particular patient population that has very aggressive tumors, and I think seeing this improvement in PFS does establish it as a potential new first-line standard of care treatment for this patient population.
